WO2012161520A3 - Composition liquide injectable contenant du docétaxel - Google Patents

Composition liquide injectable contenant du docétaxel Download PDF

Info

Publication number
WO2012161520A3
WO2012161520A3 PCT/KR2012/004087 KR2012004087W WO2012161520A3 WO 2012161520 A3 WO2012161520 A3 WO 2012161520A3 KR 2012004087 W KR2012004087 W KR 2012004087W WO 2012161520 A3 WO2012161520 A3 WO 2012161520A3
Authority
WO
WIPO (PCT)
Prior art keywords
injectable
composition containing
liquid composition
docetaxel
containing docetaxel
Prior art date
Application number
PCT/KR2012/004087
Other languages
English (en)
Korean (ko)
Other versions
WO2012161520A2 (fr
Inventor
신동철
박효주
오준교
이봉용
Original Assignee
에스케이케미칼 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이케미칼 주식회사 filed Critical 에스케이케미칼 주식회사
Publication of WO2012161520A2 publication Critical patent/WO2012161520A2/fr
Publication of WO2012161520A3 publication Critical patent/WO2012161520A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne une composition injectable contenant du docétaxel, ladite composition injectable comprenant : du docétaxel ou des sels pharmaceutiquement acceptables de celui-ci ; une HP-β-CD ; et un solvant, 30 % en volume ou plus dudit solvant total étant constitué d'éthanol et la composition injectable comprenant, en outre, une polyvinylpyrrolidone pour faciliter la dissolution de la HP-β-CD. La composition liquide transparente injectable selon l'invention a non seulement une stabilité à la conservation supérieure mais aussi une stabilité très supérieure à la dilution dans un perfusat, de sorte que la composition ne précipite pas quand elle est diluée avec un perfusat.
PCT/KR2012/004087 2011-05-23 2012-05-23 Composition liquide injectable contenant du docétaxel WO2012161520A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2011-0048225 2011-05-23
KR20110048225 2011-05-23

Publications (2)

Publication Number Publication Date
WO2012161520A2 WO2012161520A2 (fr) 2012-11-29
WO2012161520A3 true WO2012161520A3 (fr) 2013-03-21

Family

ID=47217905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2012/004087 WO2012161520A2 (fr) 2011-05-23 2012-05-23 Composition liquide injectable contenant du docétaxel

Country Status (1)

Country Link
WO (1) WO2012161520A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111728940A (zh) * 2015-03-16 2020-10-02 湖南省金准医疗科技有限公司 含有紫杉烷-环糊精复合物的药物组合物、制造方法和使用方法
WO2020019363A1 (fr) * 2018-07-25 2020-01-30 比卡生物科技（广州）有限公司 Composition de docétaxel pour injection et son procédé de préparation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090093581A (ko) * 2008-02-29 2009-09-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
KR20090101145A (ko) * 2006-05-22 2009-09-24 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물의 제조방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090101145A (ko) * 2006-05-22 2009-09-24 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물의 제조방법
KR20090093581A (ko) * 2008-02-29 2009-09-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물

Also Published As

Publication number Publication date
WO2012161520A2 (fr) 2012-11-29

Similar Documents

Publication Publication Date Title
WO2014066468A8 (fr) Formulation d'anticorps, stable, à faible viscosité
PH12017500838A1 (en) Solution comprising nicotine in unprotonated form and protonated form
AR088382A1 (es) Formulaciones de etanercept estabilizadas con xilitol
NZ709958A (en) Enhanced stability of novel liquid compositions
CL2015000051A1 (es) Una composicion farmaceutica acuosa estabilizada para almacenamiento a largo plazo que comprende etanercept y un estabilizante para prevenir, inhibir o reducir la presencia de particulas subvisibles en la composicion, donde el estabilizante comprende un tensioactivo, y donde la composicion esta libre de arginina como estabilizante.
MX362807B (es) Formulacion estabilizada de pemetrexed.
WO2011146583A3 (fr) Formulations de cinacalcet nanoparticulaire
WO2013129889A9 (fr) Film à haute teneur et à dissolution rapide à goût amer masqué comprenant du sildénafil comme principe actif
RU2015122023A (ru) Стабилизированная композиция пеметрекседа
PH12014502567A1 (en) Piperidine derivatives for gpr119 agonist
BR112014025041B8 (pt) Composição farmacêutica
WO2015171460A3 (fr) Formulations d'un concentré liquide de cyclophosphamide
MX2016011290A (es) Composiciones de ester de colina de acido lipoico y metodos de uso.
CA2904820C (fr) Compose de pyridinylpyrazoloquinoline
PH12015501312A1 (en) Solid dispersion with improved solubility comprising tetrazole derivative as an active ingredient
CL2012003488A1 (es) Formulación intravenosa que comprende una solución acuosa de sulfobutil-eter-beta-ciclodextrina y amiodarona o una sal en proporción entre 2,7: 1 a 7:1; metodo de preparación; un artículo manufacturado, util en arritmias.
WO2015173427A3 (fr) Composition a action rapide d'insuline comprenant un compose anionique substitue et un compose polyanionique
WO2014121055A3 (fr) Modulateurs flap
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
WO2012161520A3 (fr) Composition liquide injectable contenant du docétaxel
WO2013078477A3 (fr) Solubilisation de composés curcuminoïdes et de produits de ceux-ci
JO3353B1 (ar) شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
WO2012134187A3 (fr) Composition pharmaceutique pour la prévention ou le traitement de la dégénérescence maculaire
BR112015015202B8 (pt) Composição
AR092799A1 (es) Composiciones y metodos para inhibir la precipitacion de colorantes en una bebida

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12788782

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12788782

Country of ref document: EP

Kind code of ref document: A2